1. Sports nutrition supplements and adverse events – a meta-epidemiological study of case reports specifically addressing causality assessment

   • Rickard Zeijlon
   • Victor Hantelius
   • Lina Holmqvist

   Review Open access 02 October 2021 Pages: 1 - 9

   

2. The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers

   • F. Schneider
   • D. Stamler
   • L. Rabinovich-Guilatt

   Clinical Trial Open access 01 September 2021 Pages: 11 - 18

   

3. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients

   • Egle Corrado
   • Giuseppe Dattilo
   • Cesare de Gregorio

   Clinical Trial 23 September 2021 Pages: 19 - 25

   

4. Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study

   • Sultan Tuna Akgol Gur
   • Elif Oral Ahiskalioglu
   • Ali Ahiskalioglu

   Clinical Trial 16 September 2021 Pages: 27 - 33

   

5. Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel

   • Bhargavi V. Desai
   • Misbah N. Qadri
   • Bhavin A. Vyas

   Pharmacodynamics 29 October 2021 Pages: 35 - 41

   

6. To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study

   • Xiaotong Xia
   • Nianxu Huang
   • Jinhua Zhang

   Pharmacogenetics 28 August 2021 Pages: 43 - 51

   

7. Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites

   • Zheng Liu
   • Jennifer H. Martin
   • Michael Michael

   Pharmacogenetics 04 September 2021 Pages: 53 - 64

   

8. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment

   • Akiko Watanabe
   • Tomoko Ishizuka
   • Hitoshi Ishizuka

   Pharmacokinetics and Disposition Open access 20 August 2021 Pages: 65 - 73

   

9. Correction to: Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment

   • Akiko Watanabe
   • Tomoko Ishizuka
   • Hitoshi Ishizuka

   Correction 08 September 2021 Pages: 75 - 75

10. Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients

    • Kazuki Abe
    • Kaito Shibata
    • Junichi Kawakami

    Pharmacokinetics and Disposition 19 August 2021 Pages: 77 - 87

    

11. Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy

    • Danica Michaličková
    • Jan Miroslav Hartinger
    • Elke H. J. Krekels

    Pharmacokinetics and Disposition 19 August 2021 Pages: 89 - 98

    

12. Correction to: Population pharmacokinetics‑pharmacodynamics of fondaparinux in dialysis‑dependent chronic kidney disease patients undergoing chronic renal replacement therapy

    • Danica Michaličková
    • Jan Miroslav Hartinger
    • Elke H. J. Krekels

    Correction 16 September 2021 Pages: 99 - 99

13. Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking

    • Anna Basińska-Szafrańska

    Pharmacokinetics and Disposition Open access 13 September 2021 Pages: 101 - 110

    

14. Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence

    • Josip A. Borovac
    • Mette Leth-Olsen
    • Josko Bozic

    Pharmacoepidemiology and Prescription 23 August 2021 Pages: 111 - 126

    

15. Improving medication adherence and effective prescribing through a patient-centered prescription model in patients with multimorbidity

    • J. González-Bueno
    • D. Sevilla-Sánchez
    • J. Espaulella-Panicot

    Pharmacoepidemiology and Prescription 27 August 2021 Pages: 127 - 137

    

16. The impact of PIPs on mortality and readmissions in older adults: a retrospective cohort study

    • Alfredo Jose Pardo-Cabello
    • Victoria Manzano-Gamero
    • Juan de Dios Luna

    Pharmacoepidemiology and Prescription 16 September 2021 Pages: 139 - 145

17. Restrictions on the use of placebo in new COVID-19 vaccine trials

    • Maurizio Bonati

    Point of View 30 August 2021 Pages: 147 - 148

18. Response/comments to maternal paracetamol intake and fetal ductus arteriosus closure: adding pieces to the scenery—Karel Allegaert, Michael Ceulemans, John van den Anke

    • Manfred Hauben
    • Stephen Bai
    • Vincent P. Zucal

    Letter to the Editor 26 August 2021 Pages: 149 - 149

19. European NSTEMI guidelines—return of clopidogrel?

    • Lisa Dannenberg
    • René M’Pembele
    • Amin Polzin

    Letter to the Editor Open access 15 September 2021 Pages: 151 - 153

20. CYP2D6 genetic variation in Ugandans

    • Jun Miura
    • Celestino Obua
    • Sunao Kaneko

    Letter to the Editor 27 August 2021 Pages: 155 - 157